KR20120043426A - Functional composition and health food using the same - Google Patents
Functional composition and health food using the same Download PDFInfo
- Publication number
- KR20120043426A KR20120043426A KR1020100104724A KR20100104724A KR20120043426A KR 20120043426 A KR20120043426 A KR 20120043426A KR 1020100104724 A KR1020100104724 A KR 1020100104724A KR 20100104724 A KR20100104724 A KR 20100104724A KR 20120043426 A KR20120043426 A KR 20120043426A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cough
- functional composition
- composition
- functional
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 235000013402 health food Nutrition 0.000 title description 5
- 230000000694 effects Effects 0.000 claims abstract description 68
- 206010011224 Cough Diseases 0.000 claims abstract description 49
- 239000000284 extract Substances 0.000 claims abstract description 49
- 230000002265 prevention Effects 0.000 claims abstract description 20
- 235000013361 beverage Nutrition 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 241000332371 Abutilon x hybridum Species 0.000 claims description 26
- 206010036790 Productive cough Diseases 0.000 claims description 19
- 235000020737 peppermint extract Nutrition 0.000 claims description 18
- 208000024794 sputum Diseases 0.000 claims description 18
- 210000003802 sputum Anatomy 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 16
- 235000013376 functional food Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 6
- 230000003405 preventing effect Effects 0.000 claims description 6
- 230000003449 preventive effect Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 2
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000012041 food component Nutrition 0.000 claims description 2
- 239000005417 food ingredient Substances 0.000 claims description 2
- 235000008397 ginger Nutrition 0.000 claims description 2
- 235000015206 pear juice Nutrition 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 abstract description 21
- 239000003172 expectorant agent Substances 0.000 abstract description 20
- 230000000954 anitussive effect Effects 0.000 abstract description 17
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract description 14
- 230000001387 anti-histamine Effects 0.000 abstract description 14
- 239000000739 antihistaminic agent Substances 0.000 abstract description 14
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 4
- 208000026435 phlegm Diseases 0.000 abstract description 4
- 235000001497 healthy food Nutrition 0.000 abstract 2
- 240000007707 Mentha arvensis Species 0.000 abstract 1
- 235000018978 Mentha arvensis Nutrition 0.000 abstract 1
- 235000016278 Mentha canadensis Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 235000020712 soy bean extract Nutrition 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 32
- 230000002401 inhibitory effect Effects 0.000 description 24
- 229960001340 histamine Drugs 0.000 description 16
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 14
- 230000003078 antioxidant effect Effects 0.000 description 13
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 12
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 12
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 9
- 210000003630 histaminocyte Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 8
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- -1 soybean Chemical compound 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920002055 compound 48/80 Polymers 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- YEBDWAHEIMUJQT-ZLCLUPBPSA-N (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YEBDWAHEIMUJQT-ZLCLUPBPSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- DYARIVMCYYQNNQ-UHFFFAOYSA-N 7-hydroxy-2-(3-hydroxyphenyl)chromen-4-one Chemical compound OC1=CC=CC(C=2OC3=CC(O)=CC=C3C(=O)C=2)=C1 DYARIVMCYYQNNQ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- AMEWKZJIYHFYGL-NTAHRFPFSA-N C[S+](CC[C@@H](C([O-])=O)N[14CH3])C[C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 Chemical compound C[S+](CC[C@@H](C([O-])=O)N[14CH3])C[C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 AMEWKZJIYHFYGL-NTAHRFPFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100029076 Histamine N-methyltransferase Human genes 0.000 description 1
- 108010030471 Histamine N-methyltransferase Proteins 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960003789 benzonatate Drugs 0.000 description 1
- MAFMQEKGGFWBAB-UHFFFAOYSA-N benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108091008709 muscle spindles Proteins 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960000568 zipeprol Drugs 0.000 description 1
- VSTNNAYSCJQCQI-UHFFFAOYSA-N zipeprol Chemical compound C=1C=CC=CC=1C(OC)CN(CC1)CCN1CC(O)C(OC)C1=CC=CC=C1 VSTNNAYSCJQCQI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/22—Agglomeration or granulation with pulverisation of solid particles, e.g. in a free-falling curtain
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 기침, 가래 예방 및 치료 효과를 위한 서리태, 도라지, 박하 추출 복합물을 포함하는 기능성 조성물 및 이를 이용한 건강 식품에 관한 것으로, 구체적으로 진해 활성, 거담 활성 및 항히스타민 활성을 통한 기침, 가래 예방 및 치료에 탁월한 효능을 갖는 기능성 조성물 및 이를 이용한 건강 식품에 관한 것이다. The present invention relates to a functional composition comprising a frost extract, bellflower, peppermint extract complex for cough, sputum prevention and therapeutic effect, and a health food using the same, specifically cough, sputum prevention and antitussive activity, expectorant activity and antihistamine activity A functional composition having excellent efficacy in treatment and a health food using the same.
기침은 기도 점막 자극에 의해 반사적으로 일어나는 방어기전이며, 기침과 같은 원리로 외부에서 먼지나 자극물질 등이 유입되면 우리 몸의 기관지에서는 타액과 함께 근육운동을 해서 외부로 밀어내게 되는데 이것이 객담형성의 원인이 되어 폐 등 기관지의 염증에 의해서 짙은 화농성 객담이 생기게 되는 것이다.Cough is a defense mechanism that occurs reflexively by airway mucosal stimulation. When dust or irritant is introduced from the outside, the body's bronchus is pushed to the outside by muscle movement along with saliva. Caused by inflammation of the bronchus, such as the lungs, dark purulent sputum will be generated.
후두, 기관, 기관지, 인두, 횡경막 등의 기침 수용체가 물리?화학적 요인으로 인해 자극되면 연수 부위의 기침 중추에 자극이 전달되어 기침 반사가 일어나게 된다. 이렇게 일어난 기침은 연수의 해소 중추를 억제하여 기침을 조절하거나 말초에 있는 신장 수용체(stretch receptor)를 조절하여 기침을 조절하는 방법이 사용되고 있다. 연수의 해소 중추를 억제하는 약물로는 코데인(codeine), 덱스트로메토르판(dextromethorphan), 노스캡핀(noscapine), 에페드린(ephedrine), 지페프롤(zipeprol)등이 있는데 이러한 성분들은 종종 혈전반응, 심근경색, 호흡억제, 위장장애 등의 부작용을 유발하기도 한다. 이 같은 단점을 보완하여 개발된 말초의 신장 수용체(stretch receptor)를 조절하는 약물로는 레보프로피진(levopropizine), 벤조나테이트(benzonatate), 벤조자인(benzozaine), 벤질알콜(benzyl alchol)등이 사용되고 있다.When cough receptors such as larynx, trachea, bronchus, pharynx, diaphragm are stimulated due to physico-chemical factors, the stimulus is transmitted to the cough center of the soft area, and cough reflex occurs. This cough is used to control the cough by controlling the relieving center of the soft water to control the cough or by controlling the stretch receptor in the peripheral. Drugs that inhibit the softening centers include codeine, dextromethorphan, noscapine, ephedrine, and zipeprol, which are often thrombotic. It can also cause side effects such as myocardial infarction, respiratory depression and gastrointestinal disorders. Levopropizine, benzonatate, benzozaine, and benzyl alchol are the drugs that modulate peripheral kidney receptors. It is used.
또는 부교감 신경계가 물리?화학적인 요인에 의해 활성화되면 기관지 평활근이 수축되고 따라서 기관지 경련이나 기관지 수축이 일어나 기침이 유발된다. 이때 평활근을 이완시키는 베타 2 아고니스트(β-2-adrenergic receptor agonist)로써 클렌부테롤(clenbuterol), 밤부테롤(bambuterol), 포르모테롤(formoterol) 등의 약물이 사용되고 있다.Alternatively, when the parasympathetic nervous system is activated by physical and chemical factors, bronchial smooth muscle contracts, and thus bronchial spasm or bronchial contraction occurs, which causes coughing. At this time, as a
기관지 천식은 가장 대표적인 알레르기성 호흡기 질환으로 기도로 흡입된 항원(allergen)에 의해 생체내에 존재하는 다양한 면역세포로부터 순차적으로 여러 종류의 인터루킨(interleukines)들이 분비되고, 이들에 의해 비만세포(mast cell)로부터 류코트리엔(leukotrienes), 프로스타글란딘(prostaglandins), 히스타민(histamine)등이 분비되어 일어나는데, 1차적으로 급성기관지수축이 유발되고 이어서 다시 2차적인 기관지 수축이 일어나는 염증 반응이다. 천식의 치료에는 주로 기관지 확장제 약물인 디소디움 크로모글리케이트(disodium cromoglycate), 크로모린 소디움(cromolyn sodium), 네도크로밀 소디움(nedcromil sodium), 케토티펜(ketotifen) 등이 사용되고 있으며, 최근에는 새로운 기관지 이완제 및 천식에 관여하는 다양한 염증 반응들에 초점을 둔 염증 매개 인자들의 생성 저해제 또는 대사 저해제 등을 이용한 약물의 개발도 진행되고 있다.Bronchial asthma is the most typical allergic respiratory disease and various types of interleukines are sequentially secreted from various immune cells in vivo by allergens inhaled into the airways, thereby causing mast cells. Leukotrienes, prostaglandins, histamines, etc. are secreted from inflammatory reactions that primarily cause acute bronchial contraction and then secondary bronchial contraction. Asthma is mainly used for the treatment of bronchodilators such as disodium cromoglycate, cromolyn sodium, nedocromil sodium, ketotifen, etc. The development of drugs using inhibitors or metabolic inhibitors of inflammatory mediators focused on various inflammatory reactions involved in bronchial relaxants and asthma.
대부분의 거담제는 식물 등을 이용하여 민간약 또는 경험처방으로 사용하여 왔고, 최근 사용되는 약물로는 카르보시스테인(carbocysteine), N-아세틸시스테인(N-acetylcysteine) 등과 같은 시스테인유도체가 사용되고 있다. 그러나 이러한 약물들이 완전히 만족할 만한 효과를 갖고 있지 않으며, 독성이 강하고 화학적으로 불안정한 문제점을 갖고 있기 때문에 독성이 적고, 부작용이 없으며, 우수한 거담효과를 갖는 거담제의 개발이 요구되어 왔다.Most expectorants have been used as folk medicine or empirical prescriptions using plants, and recently used drugs include cysteine derivatives such as carbocysteine and N-acetylcysteine. However, since these drugs do not have a completely satisfactory effect, have a strong toxicity and chemically unstable problems, development of expectorants with low toxicity, no side effects, and excellent expectorant effects has been required.
이에 본 출원인은 천연 추출물로부터 진해 활성, 거담 활성 및 항히스타민 활성을 과학적인 방법을 통해 연구하였으며, 그 결과 기침 예방 및 치료에 탁월한 효능을 갖는 기능성 조성물을 제조하게 되었다.Accordingly, the present applicant has studied the antitussive activity, expectorant activity and antihistamine activity from natural extracts through scientific methods, and as a result, a functional composition having excellent efficacy in preventing and treating cough has been prepared.
본 발명은 상기한 문제점을 감안하여 창안된 것으로서, 기침, 가래 예방 및 치료를 위한 시도로서 항산화 활성을 측정하고, 염증완화 효과를 COX(cyclooxygenase), LO(lipoxygenase) 억제활성을 통해 확인하며, 항알레르기 효과를 비만세포로부터 히스타민분비를 억제하는 항히스타민 작용을 확인하여, 최종적으로 동물실험을 통해 진해 활성, 거담 활성 효과를 확인하는데 있다. The present invention was devised in view of the above-mentioned problems. As an attempt to prevent and treat cough and sputum, the present invention measures antioxidant activity, and confirms anti-inflammatory effect through COX (cyclooxygenase) and LO (lipoxygenase) inhibitory activity. The allergic effect is to check the antihistamine effect of inhibiting histamine secretion from mast cells, and finally to confirm the antitussive activity and expectorant activity through animal experiments.
상기한 목적은 서리태 추출물, 도라지 추출물, 박하 추출물을 혼합한 추출 복합물을 주성분으로 포함하는 조성물 및 이를 이용한 건강 식품에 관한 것이다. The above object is directed to a composition comprising an extract complex of a frost extract, bellflower extract, and peppermint extract as a main component, and a health food using the same.
상기 목적은, 서리태 추출물, 도라지 추출물, 박하 추출물로 이루어진 군으로부터 선택된 조합을 주성분으로 함유하는 것을 특징으로 하는 기침, 가래 예방 및 치료 효과를 갖는 기능성 조성물에 의해 달성된다.The above object is achieved by a functional composition having a cough, sputum preventive and therapeutic effect, comprising as a main component a combination selected from the group consisting of frost extract, bellflower extract, and peppermint extract.
여기서, 상기 조성물은 서리태 추출물, 도라지 추출물을 주성분으로 함유하며, 박하 추출물을 부가성분으로 함유하는 것을 특징으로 한다.Here, the composition contains a frost extract, bellflower extract as a main component, it contains a peppermint extract as an additional component.
상기 조성물 중 주성분은 서리태 추출물 30~80 중량%, 도라지 추출물 1~20 중량%, 박하 추출물 0.001~5 중량%로 이루어진 것을 특징으로 한다.The main component of the composition is characterized in that consisting of 30 to 80% by weight of frost extract, 1 to 20% by weight of bellflower extract, 0.001 to 5% by weight peppermint extract.
또한, 상기 목적은, 서리태 추출물, 도라지 추출물, 박하 추출물으로 이루어진 군을 주성분으로 하는 기침, 가래 예방 및 치료 효과를 갖는 기능성 조성물 외에 꿀, 흑설탕, 배즙, 생강 등 기타 식품 성분을 함유하는 식품에 의해서도 달성된다.In addition, the above object is also used by foods containing other food ingredients such as honey, brown sugar, pear juice, ginger, etc. in addition to the functional composition having a cough, sputum prevention and treatment effect mainly composed of a group consisting of frost extract, bellflower extract, peppermint extract. Is achieved.
여기서, 상기 식품은 분말, 과립, 정제, 캡슐, 액상 또는 음료 형태인 것을 특징으로 한다.Here, the food is characterized in that the powder, granules, tablets, capsules, liquid or beverage form.
그리고, 상기 목적은, 서리태 추출물, 도라지 추출물, 박하 추출물로 이루어진 군을 주성분으로 하는 기침, 가래 예방 및 치료 효과를 갖는 기능성 조성물 외에 식품학적으로 허용 가능한 비타민을 포함한 식품보조 첨가제를 포함하는 건강 기능성 식품에 의해서도 달성된다.In addition, the above object, a health functional food containing a food supplement additive including food acceptable foods in addition to the functional composition having a cough, phlegm prevention and treatment effect mainly composed of a group consisting of frost extract, bellflower extract, peppermint extract It is also achieved by
여기서, 상기 건강 기능성 식품은 분말, 과립, 정제, 캡슐 또는 음료 형태인 것을 특징으로 한다.Here, the health functional food is characterized in that the powder, granules, tablets, capsules or beverage form.
본 발명은 진해 활성, 거담 활성 및 항히스타민 활성을 통한 기침 예방 및 치료 효과를 제공한다. 또한, 독성 및 부작용이 없는 식품 및 생약성분을 배합하여 편리하게 섭취하게 함으로써 기침, 가래 예방 및 치료에 우수한 효능을 얻을 수 있다.The present invention provides a cough prevention and treatment effect through antitussive activity, expectorant activity and antihistamine activity. In addition, it is possible to obtain a good efficacy in the prevention and treatment of cough, sputum by combining convenient food and herbal ingredients without toxicity and side effects.
도 1은 기능성 조성물의 DPPH 라디칼 소거 효과를 나타낸 도면,
도 2는 기능성 조성물의 SOD 유사활성을 나타낸 도면,
도 3은 기능성 조성물의 COX-2 억제 효과를 나타낸 도면,
도 4는 기능성 조성물의 5-LO 억제 효과를 나타낸 도면,
도 5는 기능성 조성물의 히스타민 유리 억제 효과를 나타낸 도면,
도 6은 기능성 조성물의 임상실험 결과를 나타낸 도면이다.1 is a diagram showing the DPPH radical scavenging effect of the functional composition,
2 is a diagram showing the SOD-like activity of the functional composition,
3 is a view showing the COX-2 inhibitory effect of the functional composition,
4 is a diagram showing the 5-LO inhibitory effect of the functional composition,
5 shows the histamine release inhibitory effect of the functional composition,
6 is a view showing the results of clinical trials of the functional composition.
본 발명은 진해 활성, 거담 활성 및 항히스타민 활성을 통한 기침 예방 및 치료에 탁월한 효능을 갖는 기능성 조성물 및 이를 이용한 건강 식품에 관한 것으로, 서리태 추출물, 도라지 추출물, 박하 추출물을 혼합한 추출 복합물을 주성분으로 한다.The present invention relates to a functional composition having excellent efficacy in preventing and treating cough through antitussive activity, expectorant activity, and antihistamine activity, and a health food using the same, comprising an extract complex of seoritae extract, bellflower extract, and peppermint extract. .
본 발명의 조성물을 유효성분으로 함유하는 기능성 식품은 독성 및 부작용이 없는 식품 및 생약성분을 배합하여 편리하게 섭취하도록 함으로써 진해 활성, 거담 활성 및 항히스타민 활성을 통한 기침 예방 및 치료 효과가 우수한 기능성 조성물을 제공한다.Functional foods containing the composition of the present invention as an active ingredient is a functional composition excellent in cough prevention and treatment effect through antitussive activity, expectorant activity and antihistamine activity by conveniently combining food and herbal ingredients without toxicity and side effects. to provide.
본 발명에서 사용되는 주된 조성물들은 다음과 같다.The main compositions used in the present invention are as follows.
서리태는 동북 아시아가 원산지인 한해살이 식물로 검정콩이라고 불리기도 하는데 예로부터 민간에서는 약콩으로 전래되고 있다. 서리태는 대두와 마찬가지로 게니스테인(genistein)과 다이제인(daizein)과 같은 이소플라본(isoflavone)을 함유하고 이는데, 상기 게니스테인은 유해한 활성산소종을 제거하여 항산화효과를 나타내며 암세포가 면역시스템에 의한 공격을 피해 살아남을 수 있게 도와주는 HSP(heat shock protein), GRPs(glucose-related protein)와 같은 스트레스성 단백질의 생성을 저해하므로써 유방, 직장 및 전립선암 등에 대한 항암작용을 나타내는 것으로 알려져 있고, 상기 다이제인은 위에서 알코올의 배출속도를 지연시킴으로써 음주 후 급격한 혈중알코올 농도상승을 억제하는 것으로 보고되어 있다.Seo-Ri-Tae is an annual plant originated from Northeast Asia and is also called black soybeans. Soytae contains isoflavones, such as genistein and daizein, like soybean, which have antioxidant effects by removing harmful free radicals and cancer cells caused by the immune system. It is known to exhibit anticancer activity against breast, rectal and prostate cancer by inhibiting the production of stress proteins such as heat shock protein (HSP) and glucose-related protein (GRPs), which help to survive the attack. Dizain is reported to inhibit the rapid rise in blood alcohol levels after drinking alcohol by delaying the rate of alcohol release in the stomach.
도라지는 길경과에 속하는 여러해살이풀로 최근에는 집단으로 재배되지만 원래는 야생 식물이다. 이명으로는 질경, 고경, 고길경, 산도라지, 길경채, 도랏이, 백약, 대약 등으로 불린다. 예부터 약용으로 식용으로 많이 이용해 오고 있으며 식용으로는 당질과 칼슘, 철분이 다량으로 함유되어 있어 독특한 쓴맛과 향긋한 효과를 더해주는 식품으로 조리되고 있다. 약용으로서의 도라지는 동의보감과 본초강목의 기록에 따르면 호흡기 계통 질환에 특효인 것으로 나타나 있으며 트리털페노이드(triterpenoid)계 사포닌, 당질 및 섬유질을 함유하고 있어 진해, 거담작용, 중추신경 억제작용, 급성 만성염, 항궤양 및 위액분비 억제작용, 혈관을 확장하여 혈압을 낮추는 혈당강하작용, 콜레스테롤 대사 개선작용, 항산화 및 항암효과 등이 있는 것으로 밝혀져 있다.Bellflower is a perennial herb belonging to the family Gilgil, recently grown in groups but originally a wild plant. Tinnitus is called as plantain, Kogyeong, Kogilgyeong, sandflower, Gilgyeongchae, Doratyi, Baekjak, medicinal. Since ancient times, it has been used a lot for medicinal purposes, and it is cooked as a food that adds a unique bitter taste and aromatic effect because it contains a large amount of sugar, calcium and iron. Medicinal bellflowers have been shown to be effective against respiratory system diseases according to Dongbogam and herbaceous wood, and contain triterpenoid-based saponins, sugars, and fiber, as well as antitussive, expectorant, central nervous system, and acute chronic inflammation. It has been found to have anti-ulcer and gastric secretion inhibitory effects, dilate blood vessels to lower blood pressure, lower cholesterol, improve cholesterol metabolism, antioxidant and anti-cancer effects.
박하는 꿀풀과에 속하며 높이 약 1 m되는 여러해살이 풀로써 정유의 70~90%가 멘톨이다. 멘톨은 진정 작용이 있고 심장핏줄을 반사적으로 넓히며 진통 작용도 있다. 박하기름은 위와 장의 감수기에 자극작용을 하며 연동운동을 세게하고 장내에 대한 방부작용도 한다. 이 두 작용이 협력하여 장내 발효를 억제하고 소화액이 잘 분비되게 하며 위와 장의 내용물을 빨리 내보낸다고 보고되어 있다. 또한 약리실험에 의하면 박하는 적은 양을 먹으면 흥분작용을 나타내며 피부의 모세핏줄을 넓히고 땀선의 분비를 촉진시켜 체온을 내리게 한다. 그리고 관상핏줄을 확장시키며 소화선의 분비를 촉진하며 리담작용, 항균작용, 소염작용을 나타낸다.Mint belongs to Lamiaceae, perennial grass about 1 m high, 70-90% of essential oil is menthol. Menthol has a calming effect, reflexively broadens the heart veins, and also has pain relief. Peppermint oil stimulates the stomach and intestinal sensitizer, hardens peristalsis, and also acts as an antiseptic to the intestines. It is reported that these two actions work together to inhibit intestinal fermentation, to allow the digestive fluid to be secreted well, and to quickly release the contents of the stomach and intestines. In addition, pharmacological experiments show that peppermint eats a small amount of excitement, widens the capillaries of the skin and promotes the secretion of sweat glands, thereby lowering body temperature. In addition, it expands the coronary blood vessels, promotes the secretion of the digestive tract, and shows reddening, antibacterial and anti-inflammatory effects.
본 발명자들은 현대인이 갖는 기관지질환(기침, 가래 등)에 대한 해결책으로서 진해 활성, 거담 활성 및 항히스타민 활성을 갖는 천연 추출 복합물을 개발하였다. 이 조성물을 과학적인 방법을 통해 실험하여 기침 예방 및 치료에 탁월한 효능을 갖고 있음을 입증하여 본 발명을 완성하였다.The present inventors have developed a natural extract complex having antitussive activity, expectorant activity and antihistamine activity as a solution to bronchial diseases (cough, sputum, etc.) of modern people. This composition was tested by scientific methods to demonstrate that it has excellent efficacy in preventing and treating cough, thereby completing the present invention.
본 발명은 서리태, 도라지, 박하로 구성되는 군으로부터 선택된 하나이상의 천연 추출물로서 진해 활성, 거담 활성 및 항히스타민 활성을 통해 기침 예방 및 치료 효능을 갖는 조성물을 제공한다. 바람직하게는 서리태, 도라지, 박하로 이루어진 식물추출복합물을 함유하는 진해 활성, 거담 활성 및 항히스타민 활성을 통해 기침 예방 및 치료 효능을 갖는 조성물을 제공한다.The present invention provides a composition having cough prevention and treatment efficacy through antitussive activity, expectorant activity and antihistamine activity as one or more natural extracts selected from the group consisting of Suritae, Bellflower, Mint. Preferably it provides a composition having a cough prevention and treatment effect through the antitussive activity, expectorant activity and antihistamine activity containing a plant extract complex consisting of seoritae, bellflower, mint.
구체적으로 이 조성물은 서리태 추출물 30~80 중량%, 도라지 추출물 1~20 중량%, 박하 0.001~5 중량%로 이루어진 것을 특징으로 한다.Specifically, the composition is characterized in that consisting of 30 to 80% by weight of frost extract, 1 to 20% by weight of bellflower extract, 0.001 to 5% by weight mint.
본 발명의 추출물들은 하기와 같이 수득될 수 있다.Extracts of the present invention can be obtained as follows.
본 발명에 사용한 서리태와 도라지는 상점에서 구입하여 사용하였다. 서리태와 도라지를 각각 세척한 후 그늘에서 충분히 건조시키고 세절하거나 분쇄한 다음, 무게의 약 1배 내지 30배의 물, 에탄올과 같은 저급 알코올 또는 이들의 혼합용매, 바람직하게는 물로 20 내지 100℃, 바람직하게는 50 내지 95℃ 추출온도에서 1시간 내지 2일, 바람직하게는 2시간 내지 5시간 동안, 1회 내지 10회, 바람직하게는 2회 내지 5회 반복적으로 열수추출, 초음파 추출, 환류냉각 추출 등의 추출방법, 더욱 바람직하게는 열수추출 방법을 수행하여 추출물을 수득한 후 이를 여과하여, 감압농축 또는 진공농축하여 추출농축액을 수득 할 수 있으며, 부가적으로 동결 건조 및 열풍건조를 통해 분말형태로 수득 가능하다.Suritae and bellflower used in the present invention were purchased from the store. After washing frost and bellflower respectively, it is dried sufficiently in the shade and shredded or pulverized, and then water of about 1 to 30 times the weight, a lower alcohol such as ethanol or a mixed solvent thereof, preferably 20 to 100 ° C. with water, Preferably hot water extraction, ultrasonic extraction, reflux cooling for 1 to 2 days, preferably 2 to 5 hours, 1 to 10 times, preferably 2 to 5 times at 50 to 95 ° C. extraction temperature. Extraction method such as extraction, more preferably hot water extraction method to obtain the extract and then filtered and concentrated under reduced pressure or vacuum to obtain the extract concentrate, additionally by powder drying through freeze drying and hot air drying Obtainable in form.
본 발명에 사용한 박하 추출물은 경동시장에서 구입하였다. 기침 예방 및 치료용 기능성 조성물을 제조하기 위해 상기에서 수득한 서리태 추출물 30~80 중량%, 도라지 추출물 1~20 중량%, 박하 0.001~5 중량%로 혼합하여 사용하였다.Peppermint extract used in the present invention was purchased from Gyeongdong market. In order to prepare a functional composition for preventing and treating cough, 30 to 80% by weight of frost extract obtained above, 1 to 20% by weight of bellflower extract, and 0.001 to 5% by weight of mint were used.
본 발명은 상기한 바와 같이 서리태, 도라지, 박하 추출 복합물을 제조하는 제조방법을 제공한다.The present invention provides a manufacturing method for producing a frosted, bellflower, peppermint extract complex as described above.
또한, 본 발명은 진해 활성, 거담 활성 및 항히스타민 활성을 통한 기침 예방 및 치료 효과를 갖는 기능성 조성물을 제공한다.The present invention also provides a functional composition having a cough prevention and treatment effect through antitussive activity, expectorant activity and antihistamine activity.
또한, 상기 원료들은 오랫동안 식품으로 사용되어 오던 것으로서 이들로부터 추출된 본 발명의 조성물 역시 독성 및 부작용 등의 문제가 없다.In addition, the raw materials have been used as food for a long time as the composition of the present invention extracted from them also has no problems such as toxicity and side effects.
상기와 같은 방법으로 얻어진 조성물의 항산화효과, 염증 억제효과 및 항히스타민 활성을 확인하였다. 또한 기침 예방 및 치료효과를 조사하기 위하여 진해 활성, 거담 활성을 조사하기 위하여 동물실험을 실시한 결과 효과적인 진해 활성 및 거담 활성을 확인하였다.The antioxidant effect, the inflammation inhibitory effect and the antihistamine activity of the composition obtained by the above method were confirmed. In addition, animal experiments were conducted to investigate the antitussive activity and expectorant activity in order to investigate the effects of cough prevention and treatment.
본 발명의 진해 활성, 거담 활성 및 항히스타민 활성을 통한 기침 예방 및 치료 효과를 갖는 기능성 조성물 총 중량에 대하여 상기 기능성 조성물을 0.1 내지 100 중량%로 포함한다.0.1 to 100% by weight of the functional composition based on the total weight of the functional composition having a cough prevention and therapeutic effect through the antitussive activity, expectorant activity and antihistamine activity of the present invention.
본 발명의 조성물을 포함하는 기능성 식품 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.It may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of functional food compositions comprising the compositions of the present invention.
본 발명에 따른 조성물을 포함하는 기능성 식품 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형으로 제형화하여 사용될 수 있다. 본 발명의 조성물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케니트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 꿀, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Functional food compositions comprising the compositions according to the invention can be used in formulated oral dosage forms, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc., respectively, according to conventional methods. Carriers, excipients and diluents that may be included in the compositions comprising the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, honey, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. Mix is prepared. In addition to simple excipients, lubricants such as magnesium stearate are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
본 발명의 조성물의 바람직한 투여량은 대상자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.1 내지 20g으로 투여하는 것이 좋다. 투여는 하루에 한번 투여 할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the compositions of the present invention vary depending on the subject's condition and weight, extent of disease, drug form, route of administration and duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered in 0.1 to 20g per day. Administration may be once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 조성물은 독성 및 부작용이 없으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.Since the composition of the present invention does not have toxicity and side effects, it can be used with confidence even for long-term use for prophylactic purposes.
본 발명의 조성물은 기침 예방 및 치료를 위한 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류, 꿀제품류 등이 있으며, 환제, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다. 이때, 식품 또는 음료 중의 상기 조성물의 양은 전체 식품 중량의 0.01 내지 50 중량%로 가할 수 있으며, 건강 음료 조성물은 100 mL 기준으로 0.01 내지 50g 비율로 가할 수 있다.The composition of the present invention can be used in a variety of food and beverages for preventing and treating cough. Foods to which the composition of the present invention may be added include various foods, for example, beverages, gums, teas, vitamin complexes, dietary supplements, honey products, and the like, pills, powders, granules, tablets, capsules or beverages. Available in form. At this time, the amount of the composition in the food or beverage may be added in 0.01 to 50% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.01 to 50g based on 100 mL.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유 할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 50 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the composition of the present invention may contain a fruit flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명의 구성에 대해 하기 실험 및 실시예를 들어 더욱 상세히 설명하지만, 본 발명의 권리범위가 하기 실험 및 실시예에만 한정되는 것은 아니다.Hereinafter, the configuration of the present invention will be described in more detail with reference to the following experiments and examples, but the scope of the present invention is not limited only to the following experiments and examples.
실시예 1. 추출물의 제조Example 1 Preparation of Extract
본 발명에 사용한 서태리와 도라지 및 박하추출물은 원료보급회사로부터 구입하였다. 서리태 추출물과 도라지 추출물을 제조하기 위해 서리태와 도라지를 각각 1kg 건조 후 마쇄하여 얻은 분말 300g을 집기병에 담은 후 물 1,800mL을 넣고 90℃에서 2시간으로 2회 반복 하여 추출한 후, 여과지(whatman No.1, England)로 감압 여과한 다음, 여과 추출물은 진공회전농축기로 60℃에서 감압 농축 후 건조하여 추출물을 수득하였다.
Seotari and bellflower and peppermint extract used in the present invention were purchased from a raw material supply company. In order to prepare a frost extract and bellflower extract 300g of powder obtained by drying and grinding 1kg frost tea and bellflower, each 1,800mL of water was added to the trash bottle and extracted twice after 2 hours at 90 ℃, filter paper (whatman No. 1, England) under reduced pressure filtration, the filtrate was concentrated under reduced pressure at 60 ℃ with a vacuum rotary condenser and dried to obtain an extract.
실시예 2. 기능성 조성물의 제조Example 2. Preparation of Functional Composition
상기 실시예 1의 서리태 추출물, 도라지 추출물, 박하 추출물을 고형분 함량 무게기준으로 각각 50g, 5g, 0.1g의 배합비로 배합하여 기침, 가래 예방 및 치료 효과를 갖는 기능성 조성물을 제조하였다.
A functional composition having a cough, sputum prevention and therapeutic effect was prepared by blending the frost extract, bellflower extract, and peppermint extract of Example 1 in a blending ratio of 50g, 5g, and 0.1g, respectively, based on the solid content weight basis.
실험예 1. 기능성 조성물의 DPPH 라디칼 소거효과Experimental Example 1. DPPH radical scavenging effect of the functional composition
실시예 2에서 제조한 기능성 조성물의 항산화 효과가 있는지 알아보기 위하여 DPPH 라디칼 소거효과를 측정하였다.DPPH radical scavenging effect was measured to see if there is an antioxidant effect of the functional composition prepared in Example 2.
0.2mM 농도가 되도록 ethanol에 용해한 DPPH를 1.5mL, 각 농도별로 용해한 기능성 조성물 0.15mL, 증류수 1.35mL을 첨가하여 30분 동안 상온에서 반응시킨 후, 520nm에서 흡광도를 측정하였다. DPPH 라디칼 소거효과(%)는 (1-(시료를 첨가한 반응군의 흡광도/시료를 첨가하지 않은 대조군의 흡광도))*100 으로 부터 구하였다. 그 결과는 50％ radical 소거효과를 나타낼 때의 sample농도 즉, 50％ scavenging concentration(SC50) 값으로 나타내었다. 양성대조군으로 비타민C를 사용하였다.1.5 mL of DPPH dissolved in ethanol to 0.2 mM concentration, 0.15 mL of functional composition dissolved in each concentration, and 1.35 mL of distilled water were added thereto, followed by reaction at room temperature for 30 minutes, and then absorbance was measured at 520 nm. DPPH radical scavenging effect (%) was calculated from (1- (absorbance of sample added reaction group / absorbance of control sample not added)) * 100. The results are expressed as the sample concentration when the 50% radical scavenging effect, ie 50% scavenging concentration (SC 50 ) value. Vitamin C was used as a positive control.
기능성 조성물의 DPPH 라디칼 소거효과는 도 1과 같이 나타났다. 기능성 조성물의 SC50값 측정결과 26.4±0.34 ppm을 나타냈고, 양성대조군으로 사용된 대표 항산화제인 vitamin C의 SC50값은 9.5±1.24 ppm으로 나타났다. 따라서 기능성 조성물은 비타민C보다 약 2.7배 낮은 DPPH 라디칼 소거효과를 나타냈지만 비타민C는 단일물질인 반면 기능성 조성물은 천연 추출 복합물인 점을 감안하면 기능성 조성물이 우수한 DPPH 라디칼 소거효과를 나타내고 있음을 확인 할 수 있다.
DPPH radical scavenging effect of the functional composition was shown in FIG. The SC 50 value of the functional composition was 26.4 ± 0.34 ppm and the SC 50 value of vitamin C, a representative antioxidant used as a positive control, was 9.5 ± 1.24 ppm. Therefore, the functional composition showed about 2.7 times lower DPPH radical scavenging effect than vitamin C. However, considering that vitamin C is a single substance while the functional composition is a natural extract complex, the functional composition shows excellent DPPH radical scavenging effect. Can be.
실험예 2. 기능성 조성물의 SOD(superoxide anion dismutase) 유사활성Experimental Example 2 superoxide anion dismutase (SOD) -like activity of the functional composition
실시예 2에서 제조한 기능성 조성물의 항산화 효과가 있는지 알아보기 위하여 SOD(superoxide anion dismutase) 유사활성을 측정하였다.Superoxide anion dismutase (SOD) -like activity was measured to see if there was an antioxidant effect of the functional composition prepared in Example 2.
각 농도별 기능성 조성물 0.05mL, 발색액(0.4mM xanthine, 0.1 M potassium phosphate buffer(pH 8.0), 0.24mM nitro blue tetraxolium) 0.5mL, 효소액(0.048unit/mL xanthine oxidase, 0.1 M potassium phosphate buffer(pH 8.5)) 0.5mL를 첨가하고 잘 혼합하여 37℃에서 20분 동안 반응시킨 후, 70mM SDS(sodium dodecyl sulfate) 1mL을 첨가하여 효소반응을 정지시켜 560nm에서 흡광도를 측정하였다. SOD 유사활성 측정 결과를 통해 superoxide anion 라디칼 포착효과(％)를 다음과 같은 식으로부터 구하였으며, 그 결과는 SC50값으로 나타내었다. Superoxide anion 라디칼 포착효과(％)=(1-(시료를 첨가한 반응군의 흡광도/시료를 첨가하지 않은 대조군의 흡광도))*1000.05 mL of functional composition for each concentration, 0.5 mL of coloring solution (0.4 mM xanthine, 0.1 M potassium phosphate buffer (pH 8.0), 0.24 mM nitro blue tetraxolium), enzyme solution (0.048 unit / mL xanthine oxidase, 0.1 M potassium phosphate buffer (pH) 8.5)) 0.5 mL was added, mixed well, and reacted at 37 ° C. for 20 minutes. Then, 1 mL of 70 mM sodium dodecyl sulfate (SDS) was added to stop the enzyme reaction, and the absorbance was measured at 560 nm. Superoxide anion radical scavenging effect (%) was obtained from the following equation through SOD-like activity measurement, and the result was expressed as SC 50 value. Superoxide anion radical scavenging effect (%) = (1- (absorbance of reaction group with sample added / absorbance of control group without sample)) * 100
기능성 조성물의 superoxide anion 라디칼 포착효과는 도 2와 같이 나타났다. 기능성 조성물의 superoxide anion 라디칼 포착효과에 대한 SC50값은 161.64±6.79ppm이고, 비타민C는 36.53±2.09ppm으로 나타났다. 따라서 기능성 조성물은 비타민C보다 약 4.4배 낮은 superoxide anion 라디칼 포착효과를 나타냈지만 DPPH 라디칼 소거효과 결과와 마찬가지로 기능성 조성물이 천연 추출 복합물인 점을 가만하면 우수한 항산화 효과를 갖고 있음을 알 수 있다.The superoxide anion radical trapping effect of the functional composition was shown in FIG. 2. The SC 50 value for the superoxide anion radical trapping effect of the functional composition was 161.64 ± 6.79ppm and vitamin C was 36.53 ± 2.09ppm. Therefore, the functional composition showed a superoxide anion radical trapping effect about 4.4 times lower than that of vitamin C. However, similar to the DPPH radical scavenging effect, the functional composition is a natural extract complex, indicating that it has an excellent antioxidant effect.
상기의 결과들을 통해 기능성 조성물이 높은 항산화 효과를 나타내고 있음을 확인하였으며, 이는 향후 기능성 조성물의 항산화 성분 분석 및 분리 동정이 필요하며 동시에 항산화 가전 연구를 통해 천연 항산화제로서의 개발 가능성을 시사하고 있다.
Through the above results, it was confirmed that the functional composition exhibits a high antioxidant effect, which requires the analysis and separation of antioxidant components of the functional composition in the future, and suggests the possibility of developing as a natural antioxidant through the study of antioxidant home appliances.
실험예 3. 기능성 조성물의 COX-2(cyclooxygenase-2) 억제효과Experimental Example 3. COX-2 (cyclooxygenase-2) inhibitory effect of functional composition
실시예 2에서 제조한 기능성 조성물의 염증 억제효과가 있는지 알아보기 위하여 COX-2(cyclooxygenase-2) 효소 억제효과를 측정하였다.COX-2 (cyclooxygenase-2) enzyme inhibitory effect was measured to see if there is an inflammation inhibitory effect of the functional composition prepared in Example 2.
사이클로옥시게나제(cyclooxygenase, COX)는 두 가지 종류로 구분되며, 아라키돈산(arachidonic acid)를 분해하여 염증을 유발하는 프로스타글란딘류(prostaglandins)를 생성한다. 이러한 물질들이 기도 내로 유입되면 염증세포를 활성화시키고 기도 점막에서 점액분비를 촉진시켜 염증 반응이 일어나게 된다. COX-1은 일정하게 발현되어 위장, 신장, 혈소판 및 혈관 등의 조직에서 생리적인 항상성을 유지하는 등 정상적 생체기능을 유지하도록 하지만, COX-2는 염증자극원에 의해 염증성 세포에서 유도되며, 염증 및 알레르기 반응을 매개하는 프로스타글란딘류를 형성한다. 그러므로 COX-2 효소의 억제 효과를 측정하여 염증 억제 효과를 확인할 수 있다.Cyclooxygenase (COX) is classified into two types, and decomposes arachidonic acid (arachidonic acid) to produce prostaglandins (prostaglandins) that cause inflammation. When these substances enter the airways, they activate the inflammatory cells and promote mucus secretion from the airway mucosa, resulting in an inflammatory response. While COX-1 is constantly expressed and maintains normal biological functions such as maintaining physiological homeostasis in tissues such as the stomach, kidneys, platelets and blood vessels, COX-2 is induced in inflammatory cells by inflammatory stimulatory sources and inflammation And prostaglandins that mediate allergic reactions. Therefore, the inhibitory effect of COX-2 enzyme can be measured to confirm the inhibitory effect.
96 well plate에 한 well당 30units/mL의 COX-2를 40μL씩 넣고, 100mM Tris-HCl buffer(pH8.0) 90μL, 30μM EDTA 20μL, 150μM hematin 20μL 그리고 농도별 기능성 조성물 20μL를 혼합하여 25℃에서 5분간 반응시키고, 5 mM TMPD 5μL와 20 mM 아라키돈산 5μL를 첨가하여 25℃에서 5분간 반응시킨 후 ELISA autoreader를 사용하여 590nm에서 흡광도를 측정하였다. COX-2 억제율(％)은 다음과 같은 식을 이용하여 50％ 저해 농도인 IC50(50％ inhibitory concentration)값으로 나타내었다. COX-2 억제율(％)=(1-(시료를 첨가한 반응군의 흡광도/시료를 첨가하지 않은 대조군의 흡광도))*100Add 40 units of 30 units / mL COX-2 per well to a 96 well plate, mix 100 μM Tris-HCl buffer (pH8.0) 90 μL, 30
기능성 조성물의 COX-2 억제 효과는 도 3에서 나타낸 바와 같이 IC50 값이 957.94±13.7ppm으로 효과적으로 COX-2를 저해하고 있음을 알 수 있다.
As shown in FIG. 3, the COX-2 inhibitory effect of the functional composition effectively inhibits COX-2 at an IC 50 value of 957.94 ± 13.7 ppm.
실험예 4. 기능성 조성물의 5-LO(5-lipoxygenase) 억제효과Experimental Example 4. 5-LO (5-lipoxygenase) inhibitory effect of the functional composition
실시예 2에서 제조한 기능성 조성물의 5-LO(5-lipoxygenase) 억제효과를 측정하였다.5-LO (5-lipoxygenase) inhibitory effect of the functional composition prepared in Example 2 was measured.
5-리폭시게나제는 비만세포내에 존재하며 아라키돈산(arachidonic acid)를 변형하여 류코트리엔류(leukotrienes)를 생성한다. 생성된 류코트리엔류는 프로스타글란딘과 마찬가지로 기도내로 유입되어 염증세포를 활성화시키고 기도 점막에서 점액분비를 촉진시켜 염증 반응 및 알레르기 반응을 일으킨다.5-lipoxygenase is present in mast cells and modifies arachidonic acid to produce leukotrienes. The produced leukotrienes, like prostaglandins, enter the airways to activate inflammatory cells and promote mucus secretion in the airway mucosa, causing inflammatory and allergic reactions.
5-LO 억제효과를 측정하기 위하여 0.1 M Trix-HCl buffer(pH8.5) 1mL에 시료 20μL와 soybean lipoxygenase(type Ⅴ, 200units/final concentration) 20μL를 넣고 25℃에서 2분간 전 반응시킨 후 최종농도가 110μM이 되도록 30μL linoleic acid를 넣고 이것이 첨가된 시간을 기점으로 25℃에서 3분간 20초 간격으로 234nm에서 흡광도를 측정하여 초기 반응속도를 구하였다. 그 결과는 IC50값으로 나타내었다. 5-LO 억제율(％)=((대조군의 초기반응속도-실험군의 초기반응속도)/대조군의 초기반응속도)*100To measure the 5-LO inhibitory effect, add 20 μL of sample and 20 μL of soybean lipoxygenase (type V, 200units / final concentration) in 1 mL of 0.1 M Trix-HCl buffer (pH8.5), and react for 2 minutes at 25 ℃. 30μL linoleic acid was added to make 110μM, and the initial reaction rate was obtained by measuring absorbance at 234nm at 20 ° C for 3 minutes at 25 ° C. The results are expressed as IC 50 values. 5-LO inhibition rate (%) = ((initial reaction rate of control group-initial reaction rate of experimental group) / initial reaction rate of control group) * 100
기능성 조성물의 5-LO 억제효과는 도 4에 나타내었다. IC50값이 1953.55±238.69ppm으로 효과적으로 5-LO를 저해하고 있음을 알 수 있다. 이 결과를 통해 기능성 조성물이 COX-2와 5-LO를 효과적으로 저해함으로써 항염증 작용 및 항알레르기 효과를 갖고 있음을 나타낸다.
5-LO inhibitory effect of the functional composition is shown in FIG. IC 50 value of 1953.55 ± 238.69 ppm effectively inhibits 5-LO. These results indicate that the functional composition has anti-inflammatory and anti-allergic effects by effectively inhibiting COX-2 and 5-LO.
실험예 5. 히스타민 유리율 측정Experimental Example 5. Histamine Free Rate Measurement
실시예 2에서 제조한 기능성 조성물의 항히스타민 효과 확인을 위해 비만세포(mast cell)로부터 히스타민 유리율을 측정하였다.In order to confirm the antihistamine effect of the functional composition prepared in Example 2, the histamine release rate was measured from mast cells.
실험쥐(SD rat)로부터 비만세포의 분리를 위하여 실험쥐를 에테르로 치사시킨 후 티로드(tyrode)용액(137mM NaCl, 2.7mM KCl, 1mM CaCl2 ?2H2O, 0.4mM NaH2PO4, 12mM NaHCO3, 5.5mM glucose) 10ml을 실험쥐의 복강내에 주입하고 2분간 복벽을 가볍게 마사지한 후 복벽에 소절개하여 복강세척액을 체취하였다. 이 세척액을 3000rpm에서 5분간 원심분리하여 상층액을 제거하고 BSA를 함유하지 않는 티로드용액을 이용하여 2회 더 세척하였다. 티로드용액으로 재부유시킨 비만세포 부유액을 1×106 cells/ml로 각 well에 분주 하여 37℃에서 10분간 안정화시킨 후 히스타민 유리제인 컴파운드 48/80(compound 48/80) 250μL와 농도별로 희석한 기능성 조성물 250μL를 넣고 티로드용액을 첨가하여 총 2.5mL이 되도록 조정하고 20분간 배양하였다. 4℃에서 히스타민 유리반응을 중지시키고 3000rpm에서 5분간 원심분리하여 상층액을 분리하였다. 상층액 10μL와 S-adenosyl(methyl-14C) methionine 1.5μL, histamine N-methyltransferase 5μL, 300mM Tris-glycine buffer(pH 6.8) 40μL, 증류수 43.5μL를 37℃에서 90분간 반응시킨 후 3 N 과염소산 20μL를 첨가하여 반응을 중지시켰다. 과염소산을 중화시키기 위하여 10 N NaOH 20μL를 첨가하였다. 그 다음 톨루엔-이소아밀 알코올(tolune-isoamyl alcohol) 1mL로 추출한 후 상층액 700μL를 얻어 cocktail 용액 3mL로 scintillation시킨 다음 β-counter를 사용하여 cpm(counts per minute) 값을 측정하였다. 히스타민양은 히스타민 표준곡선을 이용하여 산출하였고 히스타민 총량에 대한 백분율로 표시하였다. 히스타민 유리율(％)는 (실험군 히스타민 유리양/총 히스타민 유리양)*100으로 계산하였다.Rats (SD rat) Ti loading (tyrode) solution was lethal to mice with ether to the separation of the mast cells from (137mM NaCl, 2.7mM KCl,
실험쥐의 복강비만세포에서 탈과립유발물질(compound 48/80)에 의해 유도되는 히스타민의 유리억제에 관한 실험 결과는 도 5에 나타내었다. 기능성 조성물을 처리한 비만세포의 히스타민 유리율은 25.4±3.28％로 기능성 조성물을 처리하지 않은 대조군과 비교하여 히스타민 유리를 통계적으로 유의하게 억제하고 있음을 나타냈다.
Experimental results on the free inhibition of histamine induced by degranulation-causing substance (compound 48/80) in the rat peritoneal mast cells are shown in FIG. The histamine release rate of mast cells treated with the functional composition was 25.4 ± 3.28%, indicating that the histamine release was statistically significantly suppressed compared to the control group not treated with the functional composition.
실험예 6. 기능성 조성물의 진해 활성 측정Experimental Example 6. Determination of antitussive activity of functional composition
실시예 2에서 제조한 기능성 조성물의 진해 활성을 측정하기 위해 수컷 기니피그(6주령)에 기능성 조성물을 경구 투여하고 1시간 후 프레티시스모 그래프 챔버에 넣은 후 기침 유발제인 시트르산(citric acid)을 분무하여 기침을 유발 시켰다. 시트르산에 10분간 노출시키며 이때 발생하는 기침수를 15분간 측정하였다. 기능성 조성물 대산 증류수를 경구 투여 한 군을 대조군으로 하였다. In order to measure the antitussive activity of the functional composition prepared in Example 2, male guinea pigs (6 weeks old) were orally administered with the functional composition and placed in a pretismograph chamber after 1 hour, and then sprayed with citric acid, a cough inducing agent. Caused a cough. The solution was exposed to citric acid for 10 minutes, and cough water generated at this time was measured for 15 minutes. Functional composition Daesan distilled water was orally administered as a control group.
실험결과 〔표 1〕에서 나타나는 바와 같이 기능성 조성물의 기침 억제효과를 확인할 수 있다.
Experimental results As shown in [Table 1], it can confirm the cough suppression effect of the functional composition.
실험예 7. 기능성 조성물의 거담 활성 측정Experimental Example 7. Measurement of expectorant activity of the functional composition
실시예 2에서 제조한 기능성 조성물의 거담 활성을 측정하기 위해 SD rat(6주령)에 기능성 조성물을 경구 투여하고 60분 후 페놀레드(phenol red, 10 mg/kg) 0.5mL을 복강주사 하였다. 30분 후 기도를 절개하여 1mL의 생리식염수로 30분간 침적하여 페놀레드를 추출하였으며, 여기에 0.1mL의 1M NaOH를 가하고 546nm에서 흡광도를 측정하여 페놀레드의 농도로서 거담활성을 측정하였다.In order to measure the expectorant activity of the functional composition prepared in Example 2, 0.5 mL of phenol red (phenol red, 10 mg / kg) was intraperitoneally injected 60 minutes after oral administration of the functional composition to SD rats (6 weeks old). After 30 minutes, the airway was dissected and immersed in 1 mL of saline for 30 minutes to extract phenol red. 0.1 mL of 1M NaOH was added thereto, and absorbance was measured at 546 nm to measure expectoration activity as the concentration of phenol red.
그 결과를 〔표 1〕에 나타내었다. 기능성 조성물을 투여하였을 때 대조군과 비교하여 거담 활성이 약 36％ 증가한 것을 확인하였다.
The results are shown in [Table 1]. When administering the functional composition, it was confirmed that the expectorant activity was increased by about 36% compared to the control.
실험예 8. 기능성 조성물의 기침, 가래 예방 및 치료효과의 임상실험Experimental Example 8. Clinical trial of cough, sputum prevention and treatment effect of functional composition
기능성 조성물의 기침 예방 및 치료 효과를 실험하기 위하여 일반인 성인 남녀 지원자 40명을 모집하여 20명에게는 기능성 조성물 10g을 꿀 10g에 혼합하여 1일 1회 20g씩 섭취하도록 하고, 대조군에는 위약(덱스트린) 10g을 꿀 10g에 혼합하여 같은 방법으로 섭취하도록 하였다. 7일 후 자각증상을 평가하기 위하여 설문조사를 수행하였다.In order to test the effects of cough prevention and treatment of the functional composition, 40 volunteer men and women of the general public were recruited, and 20 people received 10g of the functional composition mixed with 10g of honey once a day and 20g of placebo (dextrin) in the control group. Was mixed with 10 g of honey to be taken in the same way. After 7 days, a survey was conducted to evaluate subjective symptoms.
참여한 실험 대상자는 주로 목을 많이 쓰는 직업인 학원강사, 대학교수, 영업사원 등을 대상으로 하였으며, 각 대상자의 대조군 및 기능성 조성물군 여부를 공개하지 않는 이중맹검법(double blind test)으로 실시하였다.Participants were mainly lectured instructors, university professors, sales staff, etc., who used a lot of professions, and conducted a double blind test that did not reveal the control and functional composition of each subject.
임상실험 후 설문조사를 통해 기침, 가래, 목쉼, 목마름, 상쾌함 및 부작용의 6개 도메인으로 나누어 점수를 1(효과없음)에서 5(효과높음)로 표시하여 각각 비교하여 〔표 3〕, 도 6에 나타내었다. After the clinical trials, the scores were divided into six domains of cough, sputum, sore throat, thirst, refreshing and side effects, and the scores were displayed from 1 (no effect) to 5 (high effect). Shown in
설문조사 결과 기침, 가래, 목쉼, 목마름, 상쾌함 모든 도메인에서 대조군 보다 높은 평가를 받았다. 또한 메스꺼움, 현기증 및 두통 등과 같은 부작용에 대해서는 실험대상자 40명 모두 전혀 느끼지 못했다고 대답하였다.The survey scored higher than the control group in all domains of cough, sputum, sore throat, thirst and refreshing. In addition, all 40 subjects said they could not feel any side effects such as nausea, dizziness and headache.
이상 상세히 설명하고 입증하였듯이, 본 발명은 기침 예방 및 치료 효과를 갖는 서리태, 도라지, 박하 추출 복합물을 포함하는 기능성 조성물을 제공한다. 이 기능성 조성물은 DPPH 라디칼 소거효과, SOD라디칼 포착효과를 통해 항산화효과를 갖으며, COX-2, 5-LO효소 저해효과로 염증 억제효과를 나타낸다. 또한 비만세포로부터 히스타민 유리율을 억제시켜 항알레르기 효과를 확인하였다. 동물실험을 통해 우수한 진해 활성 및 거담 활성을 갖고 있는 것으로 나타났다. 또한 임상실험을 통해 기침, 가래, 목쉼, 목마름 및 상쾌함 도메인에서 모두 우수한 평가를 받아 기침 예방 및 치료효과를 갖는 기능성 조성물로 작용할 수 있음을 확인하였다.As described and demonstrated in detail above, the present invention provides a functional composition comprising a frost extract, bellflower, peppermint extract complex having a cough prevention and treatment effect. This functional composition has antioxidant effect through DPPH radical scavenging effect and SOD radical capture effect, and exhibits inflammation inhibitory effect by COX-2 and 5-LO enzyme inhibitory effect. In addition, the antiallergic effect was confirmed by inhibiting the histamine release rate from mast cells. Animal tests have shown that they have excellent antitussive and expectorant activity. In addition, clinical trials confirmed that the cough, sputum, sore throat, thirsty and refreshing domains can all be evaluated as excellent functional composition having a cough prevention and treatment effect.
Claims (7)
상기 조성물은 서리태 추출물, 도라지 추출물을 주성분으로 함유하며, 박하 추출물을 부가성분으로 함유하는 것을 특징으로 하는 기침, 가래 예방 및 치료효과를 갖는 기능성 조성물.The method of claim 1,
The composition is a functional composition having a cough, sputum preventive and therapeutic effect, characterized in that it contains a frost extract, bellflower extract as a main component, and peppermint extract as an additional component.
상기 조성물 중 주성분은 서리태 추출물 30~80 중량%, 도라지 추출물 1~20 중량%, 박하 추출물 0.001~5 중량%로 이루어진 것을 특징으로 하는 기침, 가래 예방 및 치료 효과를 갖는 기능성 조성물.The method of claim 2,
The main component of the composition is a functional composition having a cough, sputum preventive and therapeutic effect, characterized in that consisting of 30 ~ 80% by weight of frost extract, 1 ~ 20% by weight of bellflower extract, 0.001 ~ 5% by weight peppermint extract.
상기 식품은 분말, 과립, 정제, 캡슐, 액상 또는 음료 형태인 식품.The method of claim 4, wherein
The food is in the form of a powder, granules, tablets, capsules, liquid or beverage.
상기 건강 기능성 식품은 분말, 과립, 정제, 캡슐 또는 음료 형태인 건강기능식품.The method of claim 6,
The health functional food is a health functional food in the form of powder, granules, tablets, capsules or beverages.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100104724A KR101247611B1 (en) | 2010-10-26 | 2010-10-26 | Functional composition and health food using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100104724A KR101247611B1 (en) | 2010-10-26 | 2010-10-26 | Functional composition and health food using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120043426A true KR20120043426A (en) | 2012-05-04 |
| KR101247611B1 KR101247611B1 (en) | 2013-03-26 |
Family
ID=46263614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100104724A KR101247611B1 (en) | 2010-10-26 | 2010-10-26 | Functional composition and health food using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101247611B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103584105A (en) * | 2013-11-30 | 2014-02-19 | 大连润扬科技发展有限公司 | Cough relieving and lung moisturizing cream and preparation method thereof |
| CN104383035A (en) * | 2014-11-04 | 2015-03-04 | 禤燕华 | Traditional Chinese medicine composition for treating wind-warm cough |
| CN104721767A (en) * | 2013-12-20 | 2015-06-24 | 施泽晶 | Chinese medicinal composition for treatment of children cough and preparation method thereof |
| CN104824757A (en) * | 2015-05-29 | 2015-08-12 | 高枫 | Cough-relieving beverage and making method thereof |
| CN105056055A (en) * | 2015-09-25 | 2015-11-18 | 刘瑞云 | Medicine for treating cough |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100375560B1 (en) | 2000-02-29 | 2003-03-10 | 문혜연 | Composition comprising extract of Platycodon grandiflorusjacqin A De Candolle with anti-bronchus- disease activity |
| KR20030070243A (en) * | 2002-02-21 | 2003-08-29 | 박정훈 | Fluid pressure turbine engine using a screw rotation |
| KR20040041865A (en) * | 2002-11-12 | 2004-05-20 | 김경화 | herb medicine for remedying cold |
| KR100755728B1 (en) * | 2007-01-30 | 2007-09-06 | 이영국 | Health food composition for asthma and preparation process of the same |
-
2010
- 2010-10-26 KR KR1020100104724A patent/KR101247611B1/en active IP Right Grant
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103584105A (en) * | 2013-11-30 | 2014-02-19 | 大连润扬科技发展有限公司 | Cough relieving and lung moisturizing cream and preparation method thereof |
| CN104721767A (en) * | 2013-12-20 | 2015-06-24 | 施泽晶 | Chinese medicinal composition for treatment of children cough and preparation method thereof |
| CN104383035A (en) * | 2014-11-04 | 2015-03-04 | 禤燕华 | Traditional Chinese medicine composition for treating wind-warm cough |
| CN104824757A (en) * | 2015-05-29 | 2015-08-12 | 高枫 | Cough-relieving beverage and making method thereof |
| CN105056055A (en) * | 2015-09-25 | 2015-11-18 | 刘瑞云 | Medicine for treating cough |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101247611B1 (en) | 2013-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al Snafi | Pharmacological and therapeutic importance of a review | |
| Khare | Indian herbal remedies: rational Western therapy, ayurvedic, and other traditional usage, Botany | |
| Kaur et al. | Pharmacological actions of Opuntia ficus indica: A Review | |
| Haddadian et al. | A review of Plantago plant | |
| KR100934955B1 (en) | Pharmaceutical composition and methods of using same | |
| CA2401294C (en) | An improved herbal composition having antiallergic properties and a process for the preparation thereof | |
| KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
| KR100980819B1 (en) | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof | |
| KR20060116596A (en) | Health beverage composition comprising an extract of platycodon grandiflorum, glycyrrhiza uralensis, liriope platyphylla and chaenomeles sinesis koehne for preventing a respiratory disease | |
| KR101247611B1 (en) | Functional composition and health food using the same | |
| JP2013209354A (en) | Composition for cognitive function decline improvement | |
| KR100968674B1 (en) | Herbal composition for alcoholic hangover | |
| Jalili et al. | An overview of therapeutic potentials of Taraxacum officinale (dandelion): A traditionally valuable herb with a reach historical background | |
| Srivastava et al. | Chamomile: A herbal agent for treatment of diseases of the elderly | |
| KR100549089B1 (en) | A Health Care Composition for treating or preventing intestinal disease and constipation | |
| KR100522579B1 (en) | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress | |
| CN110652552A (en) | Wound healing formula and preparation method | |
| CN106360664A (en) | Exocarpium Citri Rubrum health food with effects of relieving cough, resisting bacteria, diminishing inflammation, clearing voice and treating pharyngolaryngitis | |
| KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
| KR100830553B1 (en) | Composition comprising the mixed extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease | |
| CN110151851A (en) | Compound and its application based on a kind of Radix Glycyrrhizae medicine pair by honeysuckle | |
| Sharangi et al. | Healing indigestion: A phytotherapeutic review | |
| JP2020504144A (en) | Composition for preventing or treating gastritis or peptic ulcer | |
| TWI712417B (en) | Composition for moistening bowel and laxative and its application and functional food | |
| KR20170003153A (en) | A composition for the prevention and treatment of respiratory organ disease comprising the fractions of Asparagus cochinchinensis as an active ingredien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20160317 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20170320 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20180316 Year of fee payment: 6 |